Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders

PR Newswire 16 hours ago

Lifshitz Law PLLC Announces Investigations of LBRDA, LLYVA, PULM, and AE

Accesswire 6 days ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Business Wire 7 days ago

PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger

Accesswire 7 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, ENTO, PIK, PFC on Behalf of Shareholders

Accesswire 7 days ago

Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders

Business Wire 8 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders

PR Newswire 8 days ago

PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders

Business Wire 8 days ago

Pulmatrix and Cullgen Announce Proposed Merger

PR Newswire 8 days ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire 13 days ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire August 13, 2024

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

PR Newswire May 29, 2024

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

PR Newswire May 15, 2024

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire May 10, 2024

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

PR Newswire March 28, 2024

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

PR Newswire January 8, 2024

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire November 9, 2023

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

PR Newswire September 19, 2023

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

PR Newswire August 23, 2023

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire August 10, 2023